Clinical Trial Update: Lapatinib and Epirubicin in Treating Patients With Metastatic Breast Cancer. ICORG 06-30 [Phase 1]

View source ↗

Summary

Phase 1 study ICORG 06-30 evaluating the combination of lapatinib and epirubicin in metastatic breast cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• ELLENCE (Epirubicin hydrochloride)
• Tykerb (lapatinib)

Snippet

Sponsor: Cancer Trials Ireland | Conditions: Breast Cancer | Phase 1 | Status: COMPLETED